Significant response to margetuximab in Chinese HER2-positive metastatic breast cancer patient who progressed after second-line targeted therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001471
Abstract: Activation of the antibody-dependent cellular cytotoxicity is one of the key mechanisms of anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody treatment. Margetuximab is a fragment C (Fc)-modified chimeric anti-HER2 immunoglobulin G1 monoclonal antibody… read more here.
Keywords: margetuximab; her2; therapy; patient ... See more keywords
Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Public Health"
DOI: 10.3389/fpubh.2022.942767
Abstract: Objective To assess the economic evaluation of margetuximab plus chemotherapy over trastuzumab plus chemotherapy for women with pretreated ERBB2-positive advanced breast cancer in the United States (US) and China. Methods Based on the SOPHIA trial,… read more here.
Keywords: margetuximab; erbb2 positive; advanced breast; positive advanced ... See more keywords